Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
January 25, 2021 11:04 am ET
Delayed at least 20 minutes

Latest news, events & financials

January 25, 2021

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

January 20, 2021

Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)

January 12, 2021

U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older

View all

February 04, 2021

Earnings

Merck & Co., Inc. Q4 2020 Earnings Call

Add to Calendar Webcast

April 29, 2021

Earnings

Merck & Co., Inc. Q1 2021 Earnings Call

Add to Calendar

July 29, 2021

Earnings

Merck & Co., Inc. Q2 2021 Earnings Call

Add to Calendar

October 28, 2021

Earnings

Merck & Co., Inc. Q3 2021 Earnings Call

Add to Calendar

View all

3Q20 Merck Earnings Announcement
PDF

3Q20 Merck Other Financial Disclosures
PDF

Merck Earnings Transcript
PDF

Form 10-Q
PDF

View all

Merck & Co., Inc. Q4 2020 Earnings Call

Dial: (833) 353-0277 or (469) 886-1947
Access Code: 2268598

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Corporate responsibility

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Explore our CR report

Download ESG Progress Report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our third-quarter 2020 financial results

Merck announced third-quarter worldwide sales of $12.6 billion – an increase of 1% compared with the third quarter of 2019. Excluding the impact from foreign exchange, sales grew 2%. The company anticipates full-year 2020 revenue range to be between $47.6 billion and $48.6 billion, including a negative impact from foreign exchange of approximately 1.5%. Take […]

Next: Our third-quarter 2020 financial results